Comparative Pharmacology
Head-to-head clinical analysis: DEFERIPRONE versus DEFEROXAMINE MESYLATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEFERIPRONE versus DEFEROXAMINE MESYLATE.
DEFERIPRONE vs DEFEROXAMINE MESYLATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Deferiprone is an iron chelator that binds to ferric iron (Fe3+) to form a stable complex, promoting iron excretion in urine. It reduces iron overload in tissues and prevents iron-induced free radical damage.
Deferoxamine chelates iron by forming a stable complex (ferrioxamine) that is excreted renally, preventing iron from catalyzing free radical formation and reducing tissue damage.
75 mg/kg/day orally in three divided doses (maximum 3 g/day).
For acute iron intoxication: 1 g intramuscularly initially, then 0.5 g every 4 hours for 2 doses, then 0.5 g every 4-12 hours up to a maximum of 6 g/day. For chronic iron overload: 20-40 mg/kg/day subcutaneously over 8-12 hours via infusion pump, or 1-2 g intravenously over 8-24 hours.
None Documented
None Documented
Clinical Note
moderateMagnesium sulfate + Deferiprone
"The serum concentration of Deferiprone can be decreased when it is combined with Magnesium sulfate."
Clinical Note
moderateMagnesium salicylate + Deferiprone
"The serum concentration of Deferiprone can be decreased when it is combined with Magnesium salicylate."
Clinical Note
moderateIron sucrose + Deferiprone
"The serum concentration of Deferiprone can be decreased when it is combined with Iron sucrose."
Clinical Note
moderateIron + Deferiprone
2-3 hours (terminal elimination half-life). Due to its short half-life, multiple daily doses are required to maintain therapeutic chelation; levels decline rapidly after dose cessation.
Terminal elimination half-life is approximately 5-6 hours for the parent drug after IM or IV administration. The half-life of ferrioxamine is about 6 hours. Clinical context: repeated dosing may be needed for sustained chelation.
Primarily renal excretion as iron complex (ferrioxamine) and unchanged drug; 70-90% of a dose is recovered in urine within 24 hours, predominantly as the iron chelate. Less than 10% is eliminated in feces via biliary excretion.
Primarily renal; within 24 hours, approximately 50% of an intramuscular dose is excreted as unchanged drug and 20% as ferrioxamine (the iron chelate). Biliary excretion is minor (<10%).
Category C
Category A/B
Iron Chelator
Iron Chelator
"The serum concentration of Deferiprone can be decreased when it is combined with Iron."